.png){kind=icon}
.png){kind=icon}
Return
Immunogenicity Challenges Associated with Subcutaneous Delivery of Therapeutic Proteins
.png){kind=icon}
OA
AI
N
S
DOI：10.1007/s40259-020-00465-4.png)
.png){kind=icon}
.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
The subcutaneous route of administration has provided convenient and non-inferior delivery of therapeutic proteins compared to intravenous infusion, but there is potential for enhanced immunogenicity toward subcutaneously administered proteins in a subset of patients. Unwanted anti-drug antibody response toward proteins or monoclonal antibodies upon repeated administration is shown to impact the pharmacokinetics and efficacy of multiple biologics. Unique immunogenicity challenges of the subcutaneous route have been realized through various preclinical and clinical examples, although subcutaneous delivery has often demonstrated comparable immunogenicity to intravenous administration. Beyond route of administration as a treatment-related factor of immunogenicity, certain product-related risk factors are particularly relevant to subcutaneously administered proteins. This review attempts to provide an overview of the mechanism of immune response toward proteins administered subcutaneously (subcutaneous proteins) and comments on product-related risk factors related to protein structure and stability, dosage form, and aggregation. A two-wave mechanism of antigen presentation in the immune response toward subcutaneous proteins is described, and interaction with dynamic antigen-presenting cells possessing high antigen processing efficiency and migratory activity may drive immunogenicity. Mitigation strategies for immunogenicity are discussed, including those in general use clinically and those currently in development. Mechanistic insights along with consideration of risk factors involved inspire theoretical strategies to provide antigen-specific, long-lasting effects for maintaining the safety and efficacy of therapeutic proteins.
Keywords:
DENDRITIC CELL-MIGRATION
PHOSPHO-L-SERINE
MULTIPLE-SCLEROSIS PATIENTS
IMMUNE TOLERANCE INDUCTION
ANTIGEN-PRESENTING CELLS
HUMAN INTERFERON-BETA
REGULATORY T-CELLS
HEMOPHILIA-A MICE
LANGERHANS CELLS
FACTOR-VIII
AI Summary
Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.
Journal
IF:
6.9
Papers:
1.6K
Citations:
3.5K
Organization
Cited Papers